<DOC>
	<DOC>NCT01695746</DOC>
	<brief_summary>This observational study will evaluate the use in clinical practice and efficacy of Mircera (methoxy polyethylene glycol-epoetin beta) in stage III-IV chronic kidney disease patients not on dialysis receiving Mircera for the treatment of chronic renal anemia. Eligible patients will be followed for 24 weeks.</brief_summary>
	<brief_title>An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Stage III-IV Chronic Kidney Disease Patients Not on Dialysis With Renal Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Adult patients, 18 to 65 years of age, inclusive Patients with stage IIIIV chronic kidney disease not on dialysis Erythropoiesis stimulating agent (ESA) na√Øve with Hb &lt; 10 g/dL, or on treatment with ESAs other than Mircera and Hb within the target range of 1012 g/dL Adequate iron status as judged by the treating physician Hypersensitivity to recombinant human erythropoietin, polyethylene glycol or to any constituent of the study medication Clinically significant concomitant disease or disorder as defined by protocol Clinical suspicion of pure red cell aplasia (PRCA) Planned elective surgery during the study period , except for cataract surgery or vascular access surgery Transfusion of red blood cells in the previous 2 months Pregnant women Contraindications for Mircera according to local prescribing information or as judged by the investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>